The combined determination of proliferative activity and cell density in the prognosis of adult patients with supratentorial high-grade astrocytic tumors.

Tumor growth represents the ratio between cell gain (number of mitoses per unit of time, i.e., proliferative activity) and cell loss (number of cell deaths during the same unit of time). While in adults, proliferative activity parallels the level of malignancy in astrocytic tumors and therefore represents a useful diagnostic marker, cell loss has never been concomitantly assessed in tumors of this type. We hypothesize that cell density assessable on histologic slides represents the ratio between cell gain and cell loss. This hypothesis concerns only the diffuse type of astrocytic tumors. Proliferative activity (assessed by MIB1 antigen immunostain) and cell density were thus quantitatively assessed by means of a cell image processor in a series of 54 supratentorial astrocytic tumors of adult patients, which included 15 astrocytomas (ASTs), 18 anaplastic astrocytomas (ANAs), and 21 glioblastomas (GBMs). The results show that proliferative activity and cell density were highly correlated (P = .003) and that both correlated with histopathologic grade. The patients with a high-grade astrocytic tumor (i.e., ANA or GBM) that exhibited a low level of proliferative activity but high cell density survived for significantly shorter periods than did patients with a tumor that exhibited low proliferative activity and low cell density (P = .002). The patients with a high-grade astrocytic tumor that exhibited high proliferative activity and high cell density survived for significantly less time than did the patients with a tumor that exhibited high proliferative activity but low cell density (P < .05). A marked difference in survival periods was observed between the patients with a high-grade astrocytic tumor that exhibited a low level of proliferative activity and low cell density and the patients with a tumor that exhibited a high level of proliferative activity and high cell density (P < .001). The concomitant determination of proliferative activity and cell density seems likely to enable determination of the few adult patients who have high-grade astrocytic tumors and who will survive for a considerable period (several years).

[1]  C Decaestecker,et al.  Image cytometry analysis of Feulgen-stained nuclei in 72 lipomatous lesions including atypical lipomas and well-differentiated liposarcomas. , 1996, American journal of clinical pathology.

[2]  R. Kiss,et al.  Characterization by means of Delaunay triangulation and Voronoi paving of the influence of anti-hormone and/or anti-growth factor antibodies on the in vitro cell growth of human colorectal neoplastic cell lines. , 1996, International journal of oncology.

[3]  C Decaestecker,et al.  Stereotactic biopsies from astrocytic tumors. Diagnostic information contributed by the quantitative chromatin pattern description. , 1995, Analytical and quantitative cytology and histology.

[4]  R. Kiss,et al.  Aneuploidy occurrence in human tumours: a logical-automaton approach. , 1995, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[5]  R. Kiss,et al.  Identification of High Versus Lower Risk Clinical Subgroups in a Group of Adult Patients with Supratentorial Anaplastic Astrocytomas , 1995, Journal of neuropathology and experimental neurology.

[6]  R. Law,et al.  Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas. , 1995, Journal of neurosurgery.

[7]  R. Kiss,et al.  The characterization of nuclear-DNA content, the proliferative activity and the immunohistochemical expression of gfap, vim, leu-7, s-100, p53 and cathepsin-d in human glioblastoma multiformes (hgbms) versus human gbm cell-lines grafted into the brains of nude-mice. , 1995, International journal of oncology.

[8]  A. Raza,et al.  Novel in situ double labeling for simultaneous detection of proliferation and apoptosis. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  Charles B. Wilson,et al.  Correlation between the bromodeoxyuridine labeling index and the MIB‐1 and Ki‐67 proliferating cell indices in cerebral gliomas , 1994, Cancer.

[10]  B. Scheithauer,et al.  Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers , 1994, Cancer.

[11]  R. Kiss,et al.  Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. , 1994, Journal of neurosurgery.

[12]  S. Coons,et al.  Regional heterogeneity in the DNA content of human gliomas , 1993, Cancer.

[13]  S. Coons,et al.  Regional Heterogeneity in the Proliferative Activity of Human Gliomas as Measured by the Ki‐67 Labeling Index , 1993, Journal of neuropathology and experimental neurology.

[14]  R. Kiss,et al.  DNA Histogram Typing in a Series of 707 Tumors of the Central and Peripheral Nervous System , 1993, The American journal of surgical pathology.

[15]  M. Berger,et al.  Detection of proliferating cell nuclear antigen in gliomas and adjacent resection margins. , 1993, Neurosurgery.

[16]  C. D. James,et al.  Gene and chromosomal alterations associated with the development of human gliomas , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  R. Kiss,et al.  Characterization of factors in routine laboratory protocols that significantly influence the Feulgen reaction. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  P J Kelly,et al.  Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. , 1993, Journal of neurosurgery.

[19]  R. Kiss,et al.  Relationship between proliferative activity and ploidy level in a series of 530 human brain tumors, including astrocytomas, meningiomas, schwannomas, and metastases. , 1993, Human pathology.

[20]  M. Prados,et al.  Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling , 1993, International journal of cancer.

[21]  R. Miller,et al.  Antigenic and differentiative heterogeneity among human glioblastomas. , 1993, Cancer letters.

[22]  K. Wallner,et al.  Erratum: Good performance status of long-term disease-free survivors of intracranial gliomas (International Journal of Radiation Oncology Biology (1993) 26 (129-133)) , 1993 .

[23]  K. Wallner,et al.  Good performance status of long-term disease-free survivors of intracranial gliomas. , 1993, International journal of radiation oncology, biology, physics.

[24]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[25]  S. Vandenberg.  Current Diagnostic Concepts of Astrocytic Tumors , 1992, Journal of neuropathology and experimental neurology.

[26]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.

[27]  P. Kleihues,et al.  The Use of the Monoclonal Antibody Ki-67 in the Identification of Proliferating Cells: Application to Surgical Neuropathology , 1986, The American journal of surgical pathology.

[28]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[29]  J. Chason,et al.  Surgical Pathology of the Nervous System and Its Coverings , 1983 .

[30]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.